T-cell Lymphoma Market
- 2026 年市場規模
- USD 2.8 Bn
- 2033 年預估規模
- USD 4.3 Bn
- 年複合成長率 CAGR
- 7.1%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
T-cell Lymphoma Market, By Lymphoma Type (Peripheral T-cell Lymphoma (Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)), and T-cell Lymphoblastic Lymphoma), By Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others (Antiviral Therapy, etc.)), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
Lymphoma is the most common type of blood cancer which occurs when white blood cells called lymphocytes grow and multiply uncontrollably in the human body. Lymphocytes are a part of the immune system of the body, which travel around the body through the lymphatic system and help fight microbial infection. Lymphocytes are of two types B lymphocytes (B-cells) and T lymphocytes (T-cells). Lymphomas that develop from T lymphocytes are known as non-Hodgkin lymphomas. T-cell lymphoma can affect body parts including spleen, lymph node, bone marrow, blood, and others. T-cell lymphoma can be majorly categorized into two types i.e. peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. The symptoms associated with T-cell lymphoma depend upon the type of T-cell lymphoma. One of the most common symptom of t-cell lymphoma includes swollen lymph node or nodes. Other symptoms include swollen liver or spleen, skin rash, abnormal blood cell count, and others.
Market Dynamics
The increasing incidence of T-cell lymphoma, rising research and development activities for the development of novel therapeutics for the treatment of T-cell lymphoma are the major factors that are expected to drive growth of the global T-cell lymphoma market over the forecast period. Moreover, increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are expected to boost the global T-cell lymphoma market.
For instance, according to a review article published in the CA: A Cancer Journal for Clinicians in December 2019, it has been estimated that there are around 80,000 people suffering from non-Hodgkin lymphomas (NHL) per year in U.S. and this is expected to increase in the near future.
Key features of the study
• This report provides in-depth analysis of the global T-cell lymphoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global T-cell lymphoma market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global T-cell lymphoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global T-cell lymphoma market
Market Segmentation
• By Lymphoma Type (Revenue, USD Bn, 2021-2033)
o Peripheral T-cell Lymphoma
Cutaneous T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Angio-immuno-blastic T-cell Lymphoma
Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)
o T-cell Lymphoblastic Lymphoma
• By Therapy (Revenue, USD Bn, 2021-2033)
o Radiotherapy
o Chemotherapy
o Immunotherapy
o Stem Cell Transplantation
o Others (Antiviral Therapy, etc.)
• By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Hoffmann-La Roche Ltd
o Biocryst Pharmaceuticals Inc.
o Bristol-Myers Squibb Company
o Kyowa Kirin Co., Ltd.
o Genmab A/S, Seagen Inc.
o GlaxoSmithKline plc.
o Johnson and Johnson Private Limited
o Elorac
o Acrotech Biopharma
o Merck and Co. Inc.
o Novartis AG
o SHIONOGI & Co., Ltd.
o Spectrum Pharmaceuticals Inc.
o Bausch Health Companies Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Lymphoma Type
Market Snippet, By Therapy
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Pipeline Analysis
o PEST Analysis
o Regulatory Scenario
o Market Trends
o Key Highlights
o Reimbursement Scenario
o Mergers & Acquisitions
4. Global T-cell Lymphoma Market, By Lymphoma Type, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022-2033
Segment Trends
o Peripheral T-cell Lymphoma
Cutaneous T-cell Lymphoma
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Anaplastic Large Cell Lymphoma
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Angio-immuno-blastic T-cell Lymphoma
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o T-cell Lymphoblastic Lymphoma
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global T-cell Lymphoma Market, By Therapy, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022-2033
Segment Trends
o Radiotherapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Chemotherapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Immunotherapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Stem Cell Transplantation
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others (Antiviral Therapy, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global T-cell Lymphoma Market, By Region, 2021-2033, (USD Bn)
o Introduction
o Market Share Analysis, By Region, 2026 and 2033 (%)
o Y-o-Y Growth Analysis, For Regions, 2022-2033
o North America
o Market Size and Forecast, By Lymphoma Type, 2021-2033, (USD Bn)
o Market Size and Forecast, By Therapy, 2021-2033, (USD Bn)
o Market Size and Forecast, By Country, 2021-2033, (USD Bn)
o U.S.
o Canada
o Latin America
o Market Size and Forecast, By Lymphoma Type, 2021-2033, (USD Bn)
o Market Size and Forecast, By Therapy , 2021-2033, (USD Bn)
o Market Size and Forecast, By Country, 2021-2033, (USD Bn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
o Market Size and Forecast, By Lymphoma Type, 2021-2033, (USD Bn)
o Market Size and Forecast, By Therapy , 2021-2033, (USD Bn)
o Market Size and Forecast, By Country, 2021-2033, (USD Bn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Lymphoma Type, 2021-2033, (USD Bn)
o Market Size and Forecast, By Therapy , 2021-2033, (USD Bn)
o Market Size and Forecast, By Country, 2021-2033, (USD Bn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
o Market Size and Forecast, By Lymphoma Type, 2021-2033, (USD Bn)
o Market Size and Forecast, By Therapy , 2021-2033, (USD Bn)
o Market Size and Forecast, By Country, 2021-2033, (USD Bn)
o GCC
o Israel
o Rest of Middle East
o Africa
o Market Size and Forecast, By Lymphoma Type, 2021-2033, (USD Bn)
o Market Size and Forecast, By Therapy , 2021-2033, (USD Bn)
o Market Size and Forecast, By Region/Country, 2021-2033, (USD Bn)
o South Africa
o Central Africa
o North Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o F. Hoffmann-La Roche Ltd
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Biocryst Pharmaceuticals Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Bristol-Myers Squibb Company
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Kyowa Kirin Co., Ltd.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Genmab A/S
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Seagen Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o GlaxoSmithKline plc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Johnson and Johnson Private Limited
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Elorac
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Acrotech Biopharma
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Merck and Co. Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Novartis AG
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o SHIONOGI & Co., Ltd.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Spectrum Pharmaceuticals Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Bausch Health Companies Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們